Geode Capital Management
TCRX icon

Geode Capital Management’s TScan Therapeutics TCRX Stock Holding History

Geode Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Sell
584,811
-32,141
-5% -$34.2K ﹤0.01% 3542
2026
Q1 		$623K Buy
616,952
+54,799
+10% +$58.6K ﹤0.01% 3512
2025
Q4 		$562K Sell
562,153
-5,504
-1% -$7.97K ﹤0.01% 3548
2025
Q3 		$1.03M Buy
567,657
+1,286
+0.2% +$2.28K ﹤0.01% 3371
2025
Q2 		$822K Sell
566,371
-448,719
-44% -$648K ﹤0.01% 3393
2025
Q1 		$1.4M Buy
1,015,090
+51,833
+5% +$112K ﹤0.01% 3181
2024
Q4 		$2.93M Sell
963,257
-10,209
-1% -$46.3K ﹤0.01% 2991
2024
Q3 		$4.85M Buy
973,466
+72,967
+8% +$440K ﹤0.01% 2772
2024
Q2 		$5.27M Buy
900,499
+486,720
+118% +$3.83M ﹤0.01% 2690
2024
Q1 		$3.29M Buy
413,779
+22,133
+6% +$139K ﹤0.01% 2910
2023
Q4 		$2.28M Buy
391,646
+83,708
+27% +$383K ﹤0.01% 3053
2023
Q3 		$789K Buy
307,938
+191,047
+163% +$446K ﹤0.01% 3421
2023
Q2 		$292K Buy
116,891
+16,449
+16% +$44.1K ﹤0.01% 3869
2023
Q1 		$211K Hold
100,442
– – ﹤0.01% 4022
2022
Q4 		$163K Sell
100,442
-227
-0.2% -$557 ﹤0.01% 4204
2022
Q3 		$307K Buy
100,669
+66,568
+195% +$218K ﹤0.01% 3976
2022
Q2 		$107K Buy
34,101
+942
+3% +$2.58K ﹤0.01% 4566
2022
Q1 		$92K Buy
33,159
+7,738
+30% +$33.4K ﹤0.01% 4688
2021
Q4 		$114K Buy
25,421
+12,635
+99% +$91.2K ﹤0.01% 4691
2021
Q3 		$106K Buy
+12,786
New +$119K ﹤0.01% 4655

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Geode Capital Management's TCRX Position: Q2 2026 in Review

Geode Capital Management reduced its TScan Therapeutics (TCRX) stake by 5.2% in Q2 2026, selling an estimated $34.2K and leaving 584,811 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #3542.

Geode Capital Management first reported a position in TCRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $5.27M in Q2 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Geode Capital Management held 584,811 shares of TScan Therapeutics worth $573K as of Q2 2026.
  • Geode Capital Management sold 32,141 TScan Therapeutics shares in Q2 2026, an estimated $34.2K.
  • TScan Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3542 holding.
  • Geode Capital Management first reported a position in TScan Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Geode Capital Management's TScan Therapeutics position peaked at $5.27M in Q2 2024.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.